An Introduction to COPD
Multitargeted approaches to symptom relief and novel disease-targeting interventions are improving the clinical management of chronic obstructive pulmonary disorder (COPD). Recently approved fixed-triple therapy in a single inhaler reduces treatment burden, improves therapy compliance and symptom relief. Inhibiting pro-inflammatory eosinophils, valve surgery and airway tissue regeneration are currently being explored. Patient-focussed pulmonary rehabilitation strategies are offering a more holistic approach to care, improving well-being and quality of life for patients living with COPD.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Air pollution and respiratory diseases: Claudia Traidl-Hoffmann, EAACI 2023
Air pollution has been linked to exacerbating and causing symptoms associated with respiratory diseases, particularly impacting patients with asthma, COPD and allergic disease. touchRESPIRATORY were delighted to speak with Prof. Claudia Traidl-Hoffmann (University in Augsburg, Germany) around the symptoms associated with exposure to air pollution, the impact of air pollution on existing respiratory conditions and […]
BOREAS: phase 3 study of dupilumab in COPD: Klaus F. Rabe, ATS 2023
The phase 3 BOREAS study (NCT03930732) investigated the efficacy and safety of dupilumab for the treatment of chronic obstructive pulmonary disease with type 2 inflammation. It was a pleasure to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the aims, design, inclusion criteria and findings from the phase 3 study and the […]
Dupilumab: an investigational monoclonal antibody for COPD: Klaus F. Rabe, ATS 2023
Dupilumab is an investigational monoclonal antibody that mitigates type 2 inflammation by blocking IL-4 and IL-13 receptors in patients with COPD. We were delighted to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the unmet needs in the treatment of COPD, the association between type 2 inflammation and COPD exacerbations and the […]
Foreword touchREVIEWS in Respiratory & Pulmonary Diseases Volume 8, Issue 1, 2023
touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(1):1
Welcome to the latest issue of touchREVIEWS in Respiratory & Pulmonary Diseases, in which we bring you a range of topical and timely articles in the field of lung diseases. In this issue, we begin with an expert interview about lebrikizumab (an anti-interleukin-13 biologic) for asthma. Stanley Szefler describes the clinical trials that have helped […]
Alvelestat: An Investigational Oral Neutrophil Elastase Inhibitor for the Treatment of Alpha-1 Antitrypsin Deficiency-associated Emphysema
touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(1):6–8 DOI: https://doi.org/10.17925/USRPD.2023.8.1.6
Alpha-1 antitrypsin deficiency (AATD)-lung disease (LD) is a rare genetic disease caused by a deficiency of the alpha-1 antitrypsin (AAT) protein in the blood and lungs. Loss of the AAT protein reduces inhibition of the proteases, specifically neutrophil elastase, which digests connective tissue in the lungs.1 AATD is associated with a predisposition for developing emphysema, […]
Updated Definition of Chronic Obstructive Pulmonary Disease in the Global Initiative for Chronic Obstructive Lung Disease 2023 Executive Report: Expert Perspectives
touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(1):9–11 DOI: https://doi.org/10.17925/USRPD.2023.8.1.9
The definition of chronic obstructive pulmonary disease (COPD) has recently been reformulated better to encompass the heterogeneous nature of this lung condition.1 The new definition is broader, includes risk factors other than smoking, and aims to improve the diagnosis, management and clinical trials of a disorder with high morbidity and mortality rates.1 In this expert interview, […]
The ENHANCE trials of ensifentrine in chronic obstructive pulmonary disease: Antonio Anzueto, ATS 2023
The ENHANCE-1 and ENHANCE-2 trials investigated the efficacy and safety of ensifentrine, a novel PDE3 and PDE4 inhibitor for the treatment of patients with COPD. touchRESPIRATORY were delighted to speak with Prof. Antonio Anzueto (South Texas Veterans Healthcare System, University of Texas Health, San Antonio, TX, USA) around the aims, design, inclusion criteria and finding […]
Ensifentrine: an investigational dual phosphodiesterase 3 and 4 inhibitor for COPD: Antonio Anzueto, ATS 2023
Ensifentrine, is a dual phosphodiesterase 3 and 4 inhibitor recently investigated in the phase 3 ENHANCE trials for the treatment of COPD. touchRESPIRATORY were delighted to speak with Prof. Antonio Anzueto (South Texas Veterans Healthcare System, University of Texas Health, San Antonio, TX, USA) around the bronchodilators already available for the treatment of COPD, the […]
Ensifentrine: A First-in-class Bifunctional Drug for the Treatment of Chronic Obstructive Pulmonary Disease
touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(2):48–53 DOI: https://doi.org/10.17925/USRPD.2022.7.2.48
There is a genuine interest on the part of researchers and the pharmaceutical industry in developing so-called ‘bifunctional’ drugs – that is, single molecules with two different primary pharmacological actions.1,2 In this context, single molecules that are capable of simultaneously inducing bronchodilation and anti-inflammatory activity are a highly intriguing possibility for treating a variety of obstructive […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!